Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
2024 · Cancer Research · 13 citations
https://doi.org/10.1158/0008-5472.can-24-0798
Z
Zhengdong Liang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
112
Papers
660
Citations
13
h-index
18
i10-index
Zhengdong Liang is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Cancer Research and Treatments & Colorectal Cancer Treatments and Studies & Cancer Cells and Metastasis. The author has an h-index of 13, co-authored 96 publications.
ORCID: 0000-0003-4861-3941Papers by this author
worksMesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib
2019 · PLoS ONE · 10 citations
https://doi.org/10.1371/journal.pone.0213294
Supplementary Tables S1-S3 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.27035752
Figure S2 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.27035767
Figure S4 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.27035761
Figure S1 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.27035770
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat